Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography

Susanne Jung, Agnes Bosch, Christian Ott, Dennis Kannenkeril, Thomas Dienemann, Joanna M. Harazny, Georg Michelson & Roland E. Schmieder

Spectral-domain optical coherence tomography (SD-OCT) represents a reliable tool for retinal layer volume and thickness measurement. The aim of this study was to evaluate retinal changes indicating neurodegenerative processes in patients with end-stage renal disease (ESRD) compared to healthy controls. This was a cross-sectional, single-center study comprising 32 ESRD patients and 38 controls. Sectoral retinal nerve fiber layer (RNFL) thickness and retinal layer volumes were obtained by SD-OCT. Age- and gender-adjusted retinal layer volumes such as total retinal volume \( (p = 0.037) \), ganglion cell layer volume \( (GCL, p = 0.003) \), ganglion cell layer – inner plexiform layer volume \( (GCL-IPL, p = 0.005) \) and inner retinal layer volume \( (IRL, p = 0.042) \) of the right eye were lower in ESRD patients. Inner plexiform layer volume of both eyes \( (IPL, \text{right eye: } p = 0.017; \text{left eye: } 0.044) \) was reduced, as was RNFL thickness in the temporal superior sector \( (\text{right eye: } p = 0.016) \). A subgroup analysis excluding patients with diabetes revealed that GCL \( (p = 0.014) \) and GCL-IPL volume of the right eye \( (p = 0.024) \) and temporal superior sector of the RNFL scan \( (p = 0.021) \) in ESRD patients were still significantly thinner. We observed a decrease in several retinal layer volumes and temporal RNFL thickness indicative of retinal neurodegenerative processes in patients with ESRD.

Within the last decade, optical coherence tomography (OCT) of the eye has evolved into a helpful and promising tool to non-invasively evaluate neuronal anatomy and vascular function in patients with various diseases. Initially described by Huang et al. in 1991, the first in-vivo application in a healthy volunteer followed in 1993. Since then, various generations of OCT-devices have been developed. The evolution from time-domain to spectral-domain technology has led to an improvement of image quality, accuracy and velocity.

Nowadays, OCT has been established as a reliable high-resolution imaging technique that is frequently applied in clinical practice for the measurement of retinal layer thickness in patients with age-related macular degeneration, glaucoma, diabetic retinopathy and other causes of optic neuropathy. A decrease in RNFL thickness or volume evaluated by OCT thereby represents an indicator of atrophy due to axonal and neuronal loss and multiple studies have shown that these alterations can be detected even earlier than through funduscopy. Therefore, OCT allows a reliable estimation of axonal integrity of the anterior visual pathway.

In patients with ESRD, alterations like lenticular opacities, changes in choroidal and central corneal thickness, retinal layer thickness as well as intraocular pressure can be observed due to major fluctuations in fluid balance.

1Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany. 2Department of Nephrology and Hypertension, Paracelsus Medical School, Nuremberg, Germany. 3Department of Pathophysiology, University of Warmia and Mazury Olsztyn, Olsztyn, Poland. 4Department of Ophthalmology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany. *email: roland.schmieder@uk-erlangen.de
Results
Study population. Baseline characteristics of the study population (n = 70) are shown in Table 1. The group of patients with ESRD included 11 female (34%) and 21 male (66%) patients aged 60.3 ± 15 years with an average office BP of 130.7 ± 25/74.0 ± 11 mmHg and a mean dialysis duration of 97.5 ± 110.2 months. The group of healthy controls included 28 female (74%) and 10 male (26%) subjects aged 57.9 ± 10 years with an average office BP of 128.1 ± 13/77.3 ± 11 mmHg and a mean serum creatinine level of 0.8 ± 0.1 mg/dL. Comparing the two groups, there were no significant differences in office systolic and diastolic or mean BP as well as body mass index (BMI), HbA1c and FPG. Patients undergoing HD showed significant differences in total cholesterol, low density lipoprotein (LDL, both p < 0.001) and high density lipoprotein (HDL, p = 0.018) as well as hemoglobin (p < 0.001) and hematocrit (p = 0.001) in comparison to healthy controls.

SD-OCT measurements. As to retinal layer volume measurement, age-adjusted total retinal volume of both eyes (right eye: p = 0.014; left eye: p = 0.046) as well as GCL volume (right eye: p = 0.001; left eye: p = 0.027, see Fig. 1), IPL volume (right eye: p = 0.004; left eye: p = 0.011), GCL-IPL volumes (right eye: p = 0.001; left eye: p = 0.018) of both eyes and IRL volume of the right eye (p = 0.015) were significantly lower in patients with ESRD than in healthy subjects. After additional gender-adjustment, total retinal volume (p = 0.037), GCL (p = 0.003), GCL-IPL (p = 0.005) and IRL volumes (p = 0.042) of the right eye as well as IPL of both eyes (right eye: p = 0.017; left eye: p = 0.044) were still significantly lower in patients with ESRD.

RNFL thickness and retinal layer volume measurements obtained by SD-OCT are presented in Tables 2 and 3. With respect to RNFL thickness, age-adjusted temporal superior sectors of the circular RNFL scan of both eyes was significantly thinner in patients undergoing HD compared to healthy controls (right eye: p = 0.008; left eye: p = 0.018). After additional adjustment for gender, the significant difference in thickness of the temporal superior sector of the right eye (p = 0.016) was persistent (Fig. 1).

To eliminate potential confounding effects of diabetes mellitus on RNFL thickness and retinal layer volumes in our patients, we performed a subgroup analysis excluding the 7 patients with type 2 diabetes mellitus (T2DM) on chronic maintenance HD. This subgroup comprised 25 subjects (9 female and 16 male individuals), that were compared to healthy controls.

The results of this subgroup analysis are presented in Table 4. With respect to retinal layer volumes in this subgroup analysis, age-adjusted GCL volume of the right eye (p = 0.005), IPL volume of both eyes (right eye: p = 0.021; left eye: p = 0.025) and GCL-IPL volume of both eyes (right eye: p = 0.009; left eye: p = 0.042) were significantly thinner in HD patients compared to healthy controls. Age- and gender-adjusted analysis revealed a

Table 1. Clinical characteristics of the study population. Data are given as mean ± SD. HD – hemodialysis, BP – blood pressure, BMI – body mass index, HbA1c – glycated hemoglobin, FPG – fasting plasma glucose, eGFR – estimated glomerular filtration rate, LDL – low-density lipoprotein, HDL – high-density lipoprotein.

|                        | Healthy controls (n = 38) | HD (n = 32) | p-value  |
|------------------------|--------------------------|-------------|----------|
| Age [years]            | 57.9 ± 10                | 60.3 ± 15   | 0.468    |
| Male gender            | 10 (26%)                 | 21 (66%)    | 0.001    |
| Duration of dialysis [months] | —                      | 97.5 ± 110.2 |         |
| Systolic office BP [mmHg] | 128.1 ± 13              | 130.7 ± 25   | 0.594    |
| Diastolic office BP [mmHg] | 77.3 ± 8.8              | 74.0 ± 11    | 0.079    |
| Mean arterial pressure [mmHg] | 95.5 ± 8.4              | 94.3 ± 15    | 0.681    |
| BMI [kg/m²]            | 24.9 ± 3.3               | 24.8 ± 5.6   | 0.875    |
| HbA1c [%]              | 5.5 ± 0.3                | 5.7 ± 1.0    | 0.735    |
| FPG [mg/dL]            | 90.2 ± 10                | 95.8 ± 32    | 0.454    |
| Creatinine [mg/dL]     | 0.8 ± 0.1                | 9.8 ± 2.7    | <0.001   |
| Total cholesterol [mg/dL] | 232.3 ± 40              | 188.5 ± 46   | <0.001   |
| LDL cholesterol [mg/dL] | 155.9 ± 32              | 119.6 ± 36   | <0.001   |
| HDL cholesterol [mg/dL] | 61.7 ± 12                | 48.5 ± 15    | 0.018    |
| Hemoglobin [g/dL]      | 13.9 ± 1.2               | 11.8 ± 1.5   | <0.001   |
| Hematocrit [%]         | 41.1 ± 3.4               | 36.1 ± 5.6   | 0.001    |
significant difference in GCL volume of the right eye (p = 0.014), GCL-IPL volume of the right eye (p = 0.024) as well as INL volume of the left eye in this subgroup (p = 0.015).
In this study, the patients undergoing HD were on average younger (41.8 ± 10.8 years) than our study subjects (60.3 ± 15 years). Furthermore, duration of dialysis treatment was significantly shorter (42.05 ± 29.96 months) compared to our patients (97.5 ± 110.2 months)\(^28\). Atilgan \textit{et al.} reported a significant thinning of the RNFL in 40 eyes of 20 patients receiving HD compared to 68 eyes of 34 healthy controls. The average age of HD patients was 47.3 ± 7.3 years in the control group, those patients were younger than in the present study, but the duration of dialysis treatment (100.8 ± 42 months) was similar to our patients\(^26\). In contrast to the above mentioned studies in which left and right eyes were analyzed together, we analyzed each eye separately and differences were more prominent in the right eye, suggesting to initially focus on the right eye to detect early changes in the OCT pattern. The fact that the mean age of patients receiving HD and of healthy controls was significantly different makes it difficult to compare our findings with those of previous studies. However, the age-adjusted temporal superior sector of the circular RNFL scan in patients with ESRD was significantly thinner than in the control group (\(p = 0.023\)). This difference persisted after additional adjustment for gender (\(p = 0.021\)).

There was no significant correlation between above mentioned layer thickness and volume measurements and duration of dialysis in the group of patients with ESRD.

### Discussion

In the present study, we analyzed and compared changes in RNFL thickness and retinal layer volumes, especially the layers containing parts of the ganglion cells in two different groups of subjects, patients with ESRD and healthy controls. This is the first study to evaluate alterations of RNFL thickness as well as volumes of each retinal layer in patients with ESRD and healthy controls. This is the first study to evaluate alterations of RNFL thickness as well as volumes of each retinal layer in two different groups of subjects, patients with ESRD and healthy controls. In comparison to healthy controls, we found a significant thinning of the inferior and temporal quadrants of RNFL in patients undergoing HD, measured by OCT-3.

In the present study, we analyzed and compared changes in RNFL thickness and retinal layer volumes, especially the layers containing parts of the ganglion cells in two different groups of subjects, patients with ESRD and healthy controls. This is the first study to evaluate alterations of RNFL thickness as well as volumes of each retinal layer in two different groups of subjects, patients with ESRD and healthy controls. In comparison to healthy controls, we found a significant thinning of the inferior and temporal quadrants of RNFL in patients undergoing HD, measured by OCT-3.

In the literature, there are only few studies describing the impact of ESRD or HD on retinal thickness parameters. None of them examined retinal layer volumes in addition to RNFL thickness. Demir \textit{et al.} compared 66 eyes of 33 patients with ESRD undergoing HD or peritoneal dialysis to 20 healthy controls and reported a significant thinning of the inferior and temporal quadrants of RNFL in patients undergoing HD, measured by OCT-3. In this study, the patients undergoing HD were on average younger (41.8 ± 10.8 years) than our study subjects (60.3 ± 15 years). Furthermore, duration of dialysis treatment was significantly shorter (42.05 ± 29.96 months) compared to our patients (97.5 ± 110.2 months)\(^28\). Atilgan \textit{et al.} reported a significant thinning of the RNFL in 40 eyes of 20 patients receiving HD compared to 68 eyes of 34 healthy controls. The average age of HD patients was 47.3 ± 7.3 years in the control group, those patients were younger than in the present study, but the duration of dialysis treatment (100.8 ± 42 months) was similar to our patients\(^26\). In contrast to the above mentioned studies in which left and right eyes were analyzed together, we analyzed each eye separately and differences were more prominent in the right eye, suggesting to initially focus on the right eye to detect early changes in the OCT pattern.

### Table 3. Retinal layer volume analysis in CKD patients on HD versus healthy controls obtained by SD-OCT.

| Retinal layer volumes [mm³] | Healthy controls (n = 38) | HD (n = 32) | p-value | p-value (age-adjusted) | p-value (age- and gender-adjusted) |
|-----------------------------|---------------------------|------------|---------|------------------------|-----------------------------------|
| Retina (OD)                 | 8.51 ± 0.41               | 8.22 ± 0.45| 0.010   | 0.014                  | 0.037                             |
| Retina (OS)                 | 8.50 ± 0.40               | 8.26 ± 0.48| 0.034   | 0.046                  | 0.074                             |
| GCL (OD)                    | 1.05 ± 0.08               | 0.96 ± 0.10| <0.001  | 0.001                  | 0.003                             |
| GCL (OS)                    | 1.04 ± 0.10               | 0.98 ± 0.12| 0.016   | 0.027                  | 0.119                             |
| IPL (OD)                    | 0.88 ± 0.07               | 0.83 ± 0.08| 0.003   | 0.004                  | 0.017                             |
| IPL (OS)                    | 0.88 ± 0.07               | 0.82 ± 0.07| 0.007   | 0.011                  | 0.044                             |
| INL (OD)                    | 0.95 ± 0.08               | 0.95 ± 0.10| 0.894   | 0.954                  | 0.498                             |
| INL (OS)                    | 0.96 ± 0.08               | 0.94 ± 0.10| 0.532   | 0.606                  | 0.157                             |
| OPL (OD)                    | 0.82 ± 0.06               | 0.80 ± 0.07| 0.222   | 0.233                  | 0.552                             |
| OPL (OS)                    | 0.81 ± 0.05               | 0.80 ± 0.06| 0.446   | 0.438                  | 0.543                             |
| ONL (OD)                    | 1.67 ± 0.20               | 1.59 ± 0.22| 0.158   | 0.202                  | 0.235                             |
| ONL (OS)                    | 1.69 ± 0.18               | 1.62 ± 0.22| 0.156   | 0.195                  | 0.158                             |
| PR (OD)                     | 2.24 ± 0.08               | 2.22 ± 0.10| 0.414   | 0.426                  | 0.423                             |
| PR (OS)                     | 2.26 ± 0.07               | 2.23 ± 0.09| 0.216   | 0.217                  | 0.146                             |
| RPE (OD)                    | 0.39 ± 0.04               | 0.39 ± 0.07| 0.601   | 0.668                  | 0.678                             |
| RPE (OS)                    | 0.40 ± 0.04               | 0.40 ± 0.06| 0.779   | 0.869                  | 0.894                             |
| IRL (OD)                    | 6.27 ± 0.38               | 6.00 ± 0.43| 0.011   | 0.015                  | 0.042                             |
| IRL (OS)                    | 6.24 ± 0.38               | 6.02 ± 0.50| 0.956   | 0.976                  | 0.126                             |
| RNFL (OD)                   | 0.9 ± 0.08                | 0.98 ± 0.12| 0.366   | 0.344                  | 0.997                             |
| RNFL (OS)                   | 0.9 ± 0.12                | 0.89 ± 0.10| 0.949   | 0.809                  | 0.650                             |
| GCL-IPL (OD)                | 1.93 ± 0.15               | 1.79 ± 0.67| 0.001   | 0.001                  | 0.005                             |
| GCL-IPL (OS)                | 1.92 ± 0.17               | 1.80 ± 0.20| 0.012   | 0.018                  | 0.076                             |
signs of neurodegenerative processes. Differences between right and left side have been previously described for other parameters, e.g. carotid intima-media thickness\(^5\). To learn more about the potential difference between right and left eye, more studies evaluating both eyes separately would be of major research interest. Furthermore, in daily clinical practice, both eyes are evaluated separately as well. Therefore, this diagnostic approach offers a more accurate, clinically valid analysis and should be applied more frequently in future studies.

In the group of patients with ESRD, we found no significant correlation between retinal layer thickness or volume on the one hand and duration of dialysis on the other hand. These findings are in accordance with the above mentioned study by Pahor et al., in which no significant correlation between retinal thickness and duration of dialysis was observed\(^26\). These findings might be due to the small sample size of the groups.

In all these previous studies, patients with T2DM have been excluded previously. To eliminate potentially interfering effects of T2DM and HD or ESRD on RNFL thickness and retinal layer volume, we performed a subgroup analysis excluding all patients with ESRD suffering from T2DM. In a previous study, we observed that T2DM affected retinal layer volumes in patients without renal disease suffering from T2DM (Jung et al., “Neuronal versus vascular retinal changes in patients with type 2 diabetes mellitus compared to healthy controls”, yet unpublished data from our group). In this exploratory subanalysis, we detected significant differences in RNFL thickness of the temporal superior sector and several retinal layer volumes.

This distinction is of importance to verify the isolated effect of homeostatic disorders due to ESRD and HD on retinal layer volume, as retinal alterations, as a sign of neuronal degeneration have been previously described in patients with T2DM\(^31, 32\). For example, a cross-sectional study by Li et al. evaluating differences in retinal layer thickness by means of OCT showed a significant thinning of the layers containing parts of the ganglion cells in patients with T2DM even in the absence of early signs of diabetic retinopathy\(^31\). In 25 subjects with minimal diabetic retinopathy, van Dijk et al. found significant decreases in RNFL, IPL and ganglion cell thickness indicating neurodegenerative processes in the course of disease\(^31\). Thus, we found various retinal layer volume and RNFL thickness alterations even in the subgroup without T2DM, indicating an isolated effect of ESRD and HD on retinal neuronal alterations.

Another cardiovascular risk factor which might represent a confounding factor is the lipid profile. The influence of lipid levels on retinal layer thickness has been previously investigated. A subgroup analysis of the Gutenberg Health Study (GHS) examining the influence of various factors on retinal nerve fiber layer (RNFL) thickness in a total of 1973 subjects showed no significant association between RNFL thickness and lipid levels in the multivariable model\(^34\). Similarly, the MIPH Eye&Health Study - investigating potential determinants of peripapillary RNFL thickness - found no association between the latter and lipid levels\(^35\). The same results were found in a population-based sample of 542 subjects from the Singapore Chinese Eye Study\(^36\).

Optic neuropathy represents a common complication in patients treated with HD due to renal failure\(^37\). In the literature, various contributing factors for optic neuropathy in patients with ESRD have been postulated. Knox et al. reported a neurotoxic form of optic neuropathy in uremic patients\(^38\). Additionally, comorbidities frequently observed in HD patients such as hypertension, atherosclerosis and glucose intolerance can lead to ischemic optic neuropathy as described by Haider et al.\(^39\). The above mentioned findings of retinal thinning in patients with ESRD by Pahor et al. were attributed to subclinical chronic ischemic retinopathy caused by obstructive carotid artery disease\(^26\).

Early detection of neurodegenerative changes not only plays an important role in the treatment of ophthalmological and neurological diseases such as for example glaucoma or multiple sclerosis, but also in internal

| Retinal layer volumes [mm\(^3\)] | Healthy controls (n=38) | HD without T2DM (n=25) | p-value | p-value (age-adjusted) | p-value (age- and gender-adjusted) |
|---------------------------------|------------------------|------------------------|---------|------------------------|-----------------------------------|
| Retina (OD)                     | 8.51 ± 0.41            | 8.27 ± 0.49            | 0.055   | 0.083                  | 0.161                             |
| Retina (OS)                     | 8.50 ± 0.40            | 8.26 ± 0.48            | 0.047   | 0.077                  | 0.143                             |
| GCL (OD)                        | 1.05 ± 0.08            | 0.97 ± 0.11            | 0.003   | 0.005                  | 0.014                             |
| GCL (OS)                        | 1.04 ± 0.10            | 0.98 ± 0.12            | 0.036   | 0.067                  | 0.235                             |
| IPL (OD)                        | 0.88 ± 0.07            | 0.83 ± 0.09            | 0.014   | 0.021                  | 0.057                             |
| IPL (OS)                        | 0.88 ± 0.07            | 0.82 ± 0.09            | 0.013   | 0.025                  | 0.076                             |
| INL (OD)                        | 0.95 ± 0.08            | 0.93 ± 0.07            | 0.279   | 0.364                  | 0.161                             |
| INL (OS)                        | 0.96 ± 0.08            | 0.92 ± 0.05            | 0.073   | 0.084                  | 0.015                             |
| IRL (OD)                        | 6.27 ± 0.38            | 6.03 ± 0.48            | 0.040   | 0.061                  | 0.132                             |
| IRL (OS)                        | 6.24 ± 0.38            | 6.01 ± 0.48            | 0.052   | 0.085                  | 0.170                             |
| GCL-IPL (OD)                    | 1.93 ± 0.15            | 1.80 ± 0.19            | 0.005   | 0.009                  | 0.024                             |
| GCL-IPL (OS)                    | 1.92 ± 0.17            | 1.80 ± 0.21            | 0.022   | 0.042                  | 0.145                             |
Just like subjects with diabetes mellitus or hypertension regularly undergo ocular examination, subjects suffering from ESRD might undergo ocular examination as well in the future. Therefore, SD-OCT could possibly become part of routine diagnostic screening to prevent early end-organ damage in clinical practice.

Our findings support the occurrence of retinal neurodegeneration and optic atrophy in patients with ESRD. The question remains whether the observed changes are caused by solely ocular or also cerebral, trans-synaptic neurodegenerative processes between retinal ganglion cells (the 3rd neuron of the visual pathway) and lateral geniculate nucleus (nucleus of the 4th neuron) as well as visual cortex. To quantify axonal damage and further investigate the structural integrity of white matter structures, 3T-magnetic resonance imaging (MRI)-based technique of diffusion tensor imaging (DTI) would be a non-invasive well-established diagnostic tool.

Our study is not without limitations. First, this is a cross-sectional study with a small sample size for each group, which did not allow for identification of pathogenetic mechanisms of our findings. Second, SD-OCT measurements were only done once for each participant at the same time of the day 1–2 hours after hemodialysis. To eliminate the acute effects of the hemodialysis session, it would have seemed advisable to perform two OCT-measurements, namely shortly before and after HD. However, previous studies did not find any significant acute influence of HD on OCT measurements. Third, age- and gender-adjustment made some of our findings less prominent than only age-adjusted analysis, suggesting that gender modifies the extent of neurodegenerative alterations. However, our study was too small to separately analyze male and female subjects and derive solid conclusions.

In conclusion, we found several differences in GCL volumes and temporal RNFL thickness, indicating severe neurodegenerative retinal alterations in patients with ESRD in comparison to healthy controls. The evaluation...
of both, each retinal layer volume separately and sectoral RNFL thickness allowed us to precisely analyze these changes. Furthermore, SD-OCT represents a valuable, accurate and sensitive high-resolution imaging technique to explore early retinal neurodegenerative processes in patients with ESRD. Further longitudinal studies in larger cohorts of patients are needed to assess the pathogenetic mechanisms of alterations in retinal layer thickness and volume during follow-up.

Methods

Study design. This is a cross-sectional, observational single center study comprising patients with ESRD and healthy individuals. Patients were examined at the Clinical Research Center of the Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Germany (www.crc-erlangen.de). Participants with ESRD were recruited directly from our dialysis unit and healthy controls by means of advertisements in local newspapers. Patients who were eligible and gave their written informed consent were enrolled consecutively. Written informed consent was obtained from each subject before study inclusion. The studies were conducted according to the tenets of the Declaration of Helsinki and the principles of good clinical practice guidelines. The study protocol has been approved by the local Ethics Committee of the University of Erlangen-Nuremberg.

Study population. A total of 70 consecutive subjects were included into the study. The group of healthy controls consisted of 38 individuals aged 40 years and older without any relevant pre-existing medical condition or medication which might possibly influence OCT measurement. Subjects with pre-existing glaucoma, macular
degeneration, diabetic retinopathy or uncontrolled hypertension and patients who had previously undergone laser coagulation were excluded. Glaucoma, macular degeneration and diabetic retinopathy were defined according to the latest respective guidelines (Guidelines of the Professional Association of German Ophthalmologists eV and the German Ophthalmology Society, Guidelines No. 15, 20 and 21). Subjects were excluded in case of presence of one of the diseases in their medical records or in case of any signs of the diseases in a funduscopic evaluation which took place prior to study inclusion. The group of patients with ESRD included 32 subjects out of 95 subjects undergoing chronic maintenance HD in our dialysis center in Nuremberg.

Clinical parameters. Demographic data of all participants were obtained and a fasting blood sample was taken to measure fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), serum creatinine, lipid levels and other biochemical parameters. Assessment of office blood pressure (BP) was carried out in standard fashion by validated devices (DINAMAP® PRO 100V2, GE Critikon) in a seated position after 5 minutes of rest according to ESH/ESC guideline recommendations47.

Ocular examination. All study subjects underwent ocular examination by the same experienced group of trained investigators in a dark room without pupil dilation. In the group of patients with ESRD, OCT measurements were done after dialysis treatment. After correct positioning of the patient, retinal layer measurements of both eyes were obtained using a high-speed, high-resolution SD-OCT system (Spectralis® OCT, Heidelberg Engineering, Heidelberg, Germany). For this purpose, a super luminescence diode (SLD) creates an infrared beam with an average wavelength of 870 nm. In order to prevent motion artefacts, SD-OCT contains an eye tracking system to compensate minimal eye movements during examination.

Macular retinal layer volumes of both eyes were determined by means of computerized segmentation, comprising total retinal volume but also each layer separately from outside to inside (see Figs. 2–4), beginning with RNFL, ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL) up to the photoreceptor layer (PRL) and retinal pigment epithelium (RPE). Additionally, GCL-IPL volume was calculated as the sum of GCL and IPL volume. Similarly, inner retinal layer (IRL) volume was calculated as the sum of RNFL, GCL and IPL volume, reflecting all three layers containing parts of the ganglion cells – axons in the RNFL, cell bodies in the GCL and dendrites in the IPL.

By means of a circular scan (average diameter 3.45 mm) which had to be positioned correctly around the participant’s pupil, SD-OCT measurements of 1024 points in the optic disc area were performed to determine RNFL thickness in six different sectors (nasal, nasal superior and inferior, temporal, temporal superior and inferior, Figs. 2 and 5). The resulting images were then analyzed and compared digitally to a normative database of n = 861 subjects by means of the Heidelberg Eye Explorer software (HEYEX) and subsequently charted as line and circle diagrams in three different colours (green: within the normal range; yellow: marginal; red: beyond the normal range).

Ocular examination was performed by the same experienced and specially trained investigators who were blinded to the respective group of subjects to reduce bias.
Statistical analysis. All analyses were performed using SPSS software, version 21.0 (IBM Corporation, Chicago, IL, USA). Data are expressed as mean ± standard deviation (SD). Normal distribution of data was confirmed by Kolmogorov-Smirnov test before further analysis. Normally distributed data were compared by unpaired Student's t-test. Not normally distributed data were compared using Wilcoxon rank sum test for non-parametric variables. A two-sided p-value < 0.05 was considered statistically significant. P-values were adjusted for age and gender. Bivariate correlation analyses were performed using Pearson's test for normally distributed parameters and Spearman's test for not normally distributed data.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 14 August 2019; Accepted: 4 February 2020;
Published online: 24 March 2020

References

1. Blumenthal, E. Z. et al. Reproducibility of nerve fiber layer thickness measurements by use of optical coherence tomography. Ophthalmol. 107, 2278–2282 (2000).
2. Schuman, J. S. et al. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmol. 103, 1889–1898 (1996).
3. Nolan, R. C., Narayana, K., Galetta, S. L. & Balcer, L. J. Optical Coherence Tomography for the Neurologist. Semin. Neurol. 35, 564–577 (2015).
4. Huang, D. et al. Optical coherence tomography. Sci. 254, 1178–1181 (1991).
5. Swanson, E. A. et al. In vivo retinal imaging by optical coherence tomography. Opt. Lett. 18, 1864–1866 (1993).
6. Chinn, S. R., Swanson, E. A. & Fujimoto, J. G. Optical coherence tomography using a frequency-tunable optical source. Opt. Lett. 22, 340–342 (1997).
7. Lalwani, G. A. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONT0 Study. Am. J. Ophthalmol. 148, 43–58 e1 (2009).
8. Schmidt-Erfurth, U., Klimscha, S., Waldstein, S. M. & Bogunovic, H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye 31, 26–44 (2017).
9. Puliafito, C. A. et al. Imaging of macular diseases with optical coherence tomography. Ophthalmol. 102, 217–229 (1995).
10. Kanamori, A. et al. Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am. J. Ophthalmol. 135, 513–520 (2003).
11. Greenfield, D. S. & Weinreb, R. N. Role of optic nerve imaging in glaucoma clinical practice and clinical trials. Am. J. Ophthalmol. 145, 597–603 (2008).
12. Lalazery, M. et al. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. Am. J. Ophthalmol. 142, 576–582 (2006).
13. Mayer, M. A., Hornger, J., Mardin, C. Y. & Tornow, R. P. Retinal Nerve Fiber Layer Segmentation on FD-OCT Scans of Normal Subjects and Glaucoma Patients. Biomed. Opt. Express 1, 1358–1383 (2010).
14. Chiablanli, J. et al. Neurodegeneration in Type 2 Diabetes: Evidence From Spectral-Domain Optical Coherence Tomography. Invest. Ophthalmol. Vis. Sci. 56, 6333–6338 (2015).
15. Goebel, W. & Kretzchmar-Gross, T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 22, 759–767 (2002).
16. Medeiros, F. A., Moura, F. C., Vessani, R. M. & Susanna, R. Jr. Axonal loss after traumatic optic neuropathy documented by optical coherence tomography. Am. J. Ophthalmol. 135, 406–408 (2003).
17. Garcia, T., Tourbah, A., Sétrouk, E., Ducasse, A. & Arndt, C. Optical coherence tomography in neuro-ophthalmology. J. Fr. Ophthalmol. 35, 454–466 (2012).
18. Garcia-Martín, E. et al. Progressive changes in the retinal nerve fiber layer in patients with multiple sclerosis. Eur. J. Ophthalmol. 20, 167–173 (2010).
19. Bodis-Wollner, I., Miki, S. & Glazman, S. Venturing into the no-man’s land of the retina in Parkinson’s disease. Mov. Disord. 29, 15–22 (2014).
20. Parisi, V. et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest. Ophthalmol. Vis. Sci. 40, 2520–2527 (1999).
21. Sengott, R. C., Frohman, E., Glanzman, R., Al-Sabbagh, A. & Panel, O. C. Ti. M. E. The role of optical coherence tomography in the management of age-related macular degeneration. Eye 22, 315–22 (2007).
22. Frohman, E. M. et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat. Clin. Pract. Neurol. 4, 664–675 (2008).
23. Lamirel, C., Newman, N. & Biousse, V. The use of optical coherence tomography in neurology. Rev. Neurol. Dis. 6, E105–120 (2009).
24. Frohman, E. M. et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch. Neurol. 65, 26–35 (2008).
25. Vrabec, R. et al. Ocular findings in patients with chronic renal failure undergoing haemodialysis. Coll. Antropol. 29(Suppl 1), 95–98 (2005).
26. Pahor, D., Gracner, B., Gracner, T. & Hojs, R. Optical coherence tomography findings in hemodialysis patients. Klin. Monbl. Augenheilkd. 225, 713–717 (2008).
27. Theodossiadis, P. G. et al. Hemodialysis-induced alterations in macular thickness measured by optical coherence tomography in diabetic patients with end-stage renal disease. Ophthalmologica. J. Int. d’ophtalmologie. Int. J. ophthalmology. Z. fur Augenheilkunde 227, 90–94 (2012).
28. Demir, M. N. et al. Retinal nerve fiber layer thickness in chronic renal failure without diabetes mellitus. Eur. J. Ophthalmol. 19, 1034–1038 (2009).
29. Atilgan, C. U. et al. Effects of hemodialysis on macular and retinal nerve fiber layer thicknesses in non-diabetic patients with end-stage renal failure. Saudi Med. J. 37, 641–647 (2016).
30. Luo, X., Yang, Y., Cao, T. & Li, Z. Differences in left and right carotid intima-media thickness and the associated risk factors. Clin. radiology 66, 393–398 (2011).
31. van Dijk, H. W. et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest. Ophthalmol. Vis. Sci. 53, 2715–2719 (2012).
32. Lu, H. T., Wang, X. N., Du, X. H. & Wu, Q. Comparison of spectral-domain optical coherence tomography for intra-retinal layers thickness measurements between healthy and diabetic eyes among Chinese adults. Plos one 12, e0177515 (2017).
33. Demir, M., Oba, E., Sensoz, H. & Ozdal, E. Retinal nerve fiber layer and ganglion cell complex thickness in patients with type 2 diabetes mellitus. Indian. J. Ophthalmol. 62, 719–720 (2014).
34. Lamparter, J. et al. Association of ocular, cardiovascular, morphometric and lifestyle parameters with retinal nerve fibre layer thickness. *Plos one* **13**, e0197682 (2018).
35. Schuster, A. K., Fischer, J. E., Vossmerbaumer, C. & Vossmerbaumer, U. Determinants of peripapillary retinal nerve fiber layer thickness regarding ocular and systemic parameters - the MIPH Eye&Health Study. *Graefes archive Clin. Exp. Ophthalmod. = Albrecht von. Graefes Arch. fur klinische und experimentelle Ophthalmodologie* **254**, 2011–2016 (2016).
36. Cheung, C. Y. et al. Determinants of quantitative optic nerve fiber measurements using spectral domain optical coherence tomography in a population-based sample of non-glaucomatous subjects. *Investig. Ophthalmod. Vis. Sci.* **52**, 9629–9635 (2011).
37. Haider, S., Austbury, N. J. & Hamilton, D. V. Optic neuropathy in uraemic patients on dialysis. *Eye* **7**(Pt 1), 148–151 (1993).
38. Knox, D. L. et al. Uremic optic neuropathy. *Arch. Ophthalmod.* **106**, 50–54 (1988).
39. Engelhorn, T., Haider, S., Michelson, G. & Doerfler, A. A new semi-quantitative approach for analysing 3T diffusion tensor imaging of optic fibres and its clinical evaluation in glaucoma. *Academic radiology* **17**, 1313–1316 (2010).
40. Pierpaoli, C., Jezzard, P., Basser, P. J., Barnett, A. & Di Chiro, G. Diffusion tensor MR imaging of the human brain. *Radiology* **201**, 637–648 (1996).
41. Melhem, E. R. et al. Diffusion tensor MR imaging of the brain and white matter tractography. *AJR. Am. J. roentgenology* **178**, 3–16 (2002).
42. Michelson, G. et al. DTI parameters of axonal integrity and demyelination of the optic radiation correlate with glaucoma indices. *Graefes archive Clin. Exp. Ophthalmod. = Albrecht von. Graefes Arch. fur klinische und experimentelle Ophthalmodologie* **251**, 243–253 (2013).
43. Engelhorn, T. et al. Diffusion tensor imaging detects rarefaction of optic radiation in glaucoma patients. *Academic radiology* **18**, 764–769 (2011).
44. Lawlor, M. et al. Glaucoma and the brain: Trans-synaptic degeneration, structural change, and implications for neuroprotection. *Surv. Ophthalmod.* **63**, 296–306 (2018).
45. Tokuyama, T., Ikeda, T. & Sato, K. Effects of haemodialysis on diabetic macular leakage. *Br. J. Ophthalmod.* **84**, 1397–1400 (2000).
46. Ulas, F. et al. Evaluation of choroidal and retinal thickness measurements using optical coherence tomography in non-diabetic haemodialysis patients. *Int. Ophthalmod.* **33**, 533–539 (2013).
47. Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur. heart J.* **34**, 2159–2219 (2013).

**Acknowledgements**

We gratefully acknowledge the expert technical assistance of Dorothea Bader-Schmieder, Ingrid Fleischmann, Kerstin Fröhlich-Endreß, Ulrike Heinritz, Wiebke Maurer, Simone Pejkovic and Sabine Thümler. The study was supported by an unrestricted research grant to A.B. provided by Novartis Pharma GmbH, Germany. No other funding source was involved in any part of the study or the decision to submit the manuscript for publication. The present work was performed in fulfillment of the requirements for obtaining the degree “Dr. med” for author S.J.

**Author contributions**

R.E.S., C.O., A.B., D.K. and J.M.H. designed the study. R.E.S., A.B., T.D., G.M. and S.J. analyzed and interpreted data. S.J. wrote the manuscript and all coauthors critically commented and/or edited the manuscript. R.E.S. supervised the project.

**Competing interests**

R.E.S. is a state employee of the Free State of Bavaria (University Hospital Erlangen)/Federal Republic of Germany. He is a member of the working group of 2013/2018 ESC/ESH guidelines for the management of arterial hypertension. R.E.S. received Speaker fees, Consultancy and Advisory Board fees from Bayer, Berlinchemie, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, Recor, ROX Medical and Servier. Research grant to the institution has been given to RES by DFG, Amgen, Ablative Solutions, Boehringer Ingelheim, Novartis, Medtronic, Recor and ROX Medical. All other authors have no conflicts of interest to declare.

**Additional information**

Correspondence and requests for materials should be addressed to R.E.S.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020